Tripos Announces its Latest Release of its Software for Drug Discovery
This latest release further extends the Tripos commitment to providing innovative, integrated software that addresses cutting-edge concerns in drug discovery such as virtual screening, chemical informatics, pharmacophore determination, and ADME. Premiering for the first time in this release are CombiFlexX?, a virtual screening program designed to identify compounds in combinatorial libraries most likely to be effective as new drugs, and HiVol?, a new cheminformatics tool for interactively analyzing and exploring large volumes of high throughput screening and synthesis data. DISCOtech? is an innovative new product that simplifies pharmacophore elucidation and the search for lead compounds, and VolSurf? is a well-respected program of proven utility in the pharmaceutical industry that predicts the ADME properties of potential new drugs.
By supporting a variety of computational platforms, the SYBYL®6.8/UNITY®4.3 release reflects Tripos Discovery Software dedication to accommodating the diverse and ever-changing informatics needs of scientists. While SYBYL, UNITY and all associated applications continue to be supported on SGI hardware, the new release extends beyond this widely recognized platform to include powerful new HP workstations and servers. In addition, FlexX? and CScore? -- part of Tripos' suite of virtual screening tools -- have now been ported to Linux®, making it possible to launch screening experiments from an SGI or HP workstation and distribute the calculations over a high-capacity network of Intel® compatible servers.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.